Sundrug Co.,Ltd. (TYO:9989)
Japan · Delayed Price · Currency is JPY 3,712.00
-5.00 (-0.13%)
Aug 21, 2026, 3:30 PM JST
Sundrug Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 850,145 | 842,512 | 801,811 | 751,777 | 690,462 | 648,734 | |
Revenue Growth | 4.32% | 5.08% | 6.65% | 8.88% | 6.43% | 2.27% |
Cost of Revenue | 631,940 | 626,341 | 597,723 | 562,457 | 518,516 | 492,228 |
Gross Profit | 218,205 | 216,171 | 204,088 | 189,320 | 171,946 | 156,506 |
Selling, General & Admin | 152,794 | 150,578 | 142,309 | 133,294 | 134,492 | 122,454 |
Operating Expenses | 171,554 | 169,338 | 159,591 | 148,323 | 134,495 | 122,454 |
Operating Income | 46,651 | 46,833 | 44,497 | 40,997 | 37,451 | 34,052 |
Interest Expense | -440 | -384 | -164 | -32 | -36 | -9 |
Interest & Investment Income | 242 | 244 | 160 | 127 | 125 | 128 |
Earnings From Equity Investments | -1,294 | -1,258 | -1,567 | - | - | - |
Other Non Operating Income (Expenses) | 820 | 785 | 908 | 636 | 594 | 563 |
EBT Excluding Unusual Items | 45,979 | 46,220 | 43,834 | 41,728 | 38,134 | 34,734 |
Gain (Loss) on Sale of Investments | 33 | - | 198 | - | - | - |
Gain (Loss) on Sale of Assets | 82 | 84 | -6 | 21 | 144 | 232 |
Asset Writedown | -572 | -900 | -998 | -856 | -864 | -282 |
Other Unusual Items | 101 | 399 | 540 | 367 | 296 | -10 |
Pretax Income | 45,623 | 45,803 | 43,568 | 41,260 | 37,710 | 34,674 |
Income Tax Expense | 14,158 | 14,411 | 12,818 | 12,134 | 12,007 | 10,821 |
Net Income | 31,465 | 31,392 | 30,750 | 29,126 | 25,703 | 23,853 |
Net Income to Common | 31,465 | 31,392 | 30,750 | 29,126 | 25,703 | 23,853 |
Net Income Growth | 0.19% | 2.09% | 5.58% | 13.32% | 7.76% | -5.83% |
Shares Outstanding (Basic) | 117 | 117 | 117 | 117 | 117 | 117 |
Shares Outstanding (Diluted) | 117 | 117 | 117 | 117 | 117 | 117 |
Shares Change | 0.01% | 0.01% | 0.02% | 0.01% | 0.01% | 0.00% |
EPS (Basic) | 268.97 | 268.36 | 262.90 | 249.06 | 219.83 | 204.02 |
EPS (Diluted) | 268.97 | 268.36 | 262.90 | 249.06 | 219.82 | 204.01 |
EPS Growth | 0.18% | 2.07% | 5.56% | 13.30% | 7.75% | -5.83% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 12,961 | 7,713 | 4,762 | 12,591 | 12,857 |
Free Cash Flow Per Share | - | 110.80 | 65.94 | 40.72 | 107.68 | 109.96 |
Dividend Per Share | 131.000 | 131.000 | 130.000 | 114.000 | 100.000 | 71.000 |
Dividend Growth | 0.77% | 0.77% | 14.04% | 14.00% | 40.84% | 1.43% |
Gross Margin | 25.67% | 25.66% | 25.45% | 25.18% | 24.90% | 24.13% |
Operating Margin | 5.49% | 5.56% | 5.55% | 5.45% | 5.42% | 5.25% |
Profit Margin | 3.70% | 3.73% | 3.84% | 3.87% | 3.72% | 3.68% |
Free Cash Flow Margin | - | 1.54% | 0.96% | 0.63% | 1.82% | 1.98% |
EBITDA | 65,781 | 65,593 | 61,779 | 56,124 | 49,519 | 44,261 |
EBITDA Margin | 7.74% | 7.79% | 7.70% | 7.47% | 7.17% | 6.82% |
D&A For EBITDA | 19,130 | 18,760 | 17,282 | 15,127 | 12,068 | 10,209 |
EBIT | 46,651 | 46,833 | 44,497 | 40,997 | 37,451 | 34,052 |
EBIT Margin | 5.49% | 5.56% | 5.55% | 5.45% | 5.42% | 5.25% |
Effective Tax Rate | 31.03% | 31.46% | 29.42% | 29.41% | 31.84% | 31.21% |